文献速递淋巴瘤造血干细胞移植与细胞治疗

慢性淋巴细胞白血病靶向治疗耐药性的克服策略

Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

该综述讨论慢性淋巴细胞白血病(CLL)靶向治疗获得性耐药的机制与应对策略。耐药机制包括药物靶点内的继发突变和旁路途径激活;预防或克服耐药的方法包括联合靶向旁路机制、按时序安排治疗、改进临床试验设计和实时监测反应。合理设计药物序贯可能保障复发时的有效选择,下一代抑制剂和双特异性抗体有望克服依鲁替尼耐药,免疫治疗(含CAR-T)正在复发CLL中探索。

要点

  • CLL靶向治疗(BCL-2、BTK、PI3K抑制剂)已获批并显著改善管理,但获得性耐药仍是挑战。
  • 耐药机制包括药物靶点继发突变和旁路途径激活,据此可设计预防与克服策略。
  • 预防耐药策略含联合靶向旁路、按时序治疗、改进试验设计与实时监测反应。

核心结论

  • CLL靶向治疗获得性耐药是待解决的挑战,机制渐明并已催生预防与克服策略。

研究设计与样本

  • 综述,讨论CLL靶向治疗耐药的最新进展与管理策略,涵盖转化、真实世界和临床视角。

主要发现

  • 耐药机制包括药物靶点内继发突变和旁路途径激活。
  • 预防耐药方法包括联合靶向旁路机制、按时序安排治疗、改进临床试验设计和实时监测患者反应。
  • 合理设计药物序贯可能保障复发时的有效治疗选择。
  • 下一代抑制剂和双特异性抗体有潜力克服BTK抑制剂依鲁替尼耐药。
  • 免疫治疗包括嵌合抗原受体修饰T细胞(CAR-T)疗法正在复发CLL中探索。

临床怎么用

  • 临床可依据耐药机制采用联合靶向旁路、时序治疗与实时监测等策略预防或克服耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Insight into the critical role of B-cell receptor signaling for the pathogenesis of chronic lymphocytic leukemia (CLL) led to the development of targeted therapies directed at key regulators of cell survival. Agents targeting B-cell lymphoma-2 protein, Bruton's tyrosine kinase (BTK), and phosphatidylinositol 3-kinase are approved for treatment of CLL, and have significantly improved the disease management. Nevertheless, acquired resistance to the targeted therapies is a challenge still to be resolved. The mechanisms underlying resistance are becoming clearer, and include secondary mutations within the drug target and activation of bypass pathways. This knowledge has allowed development of strategies to prevent and overcome treatment resistance. Approaches to prevent resistance include targeting bypass mechanisms by combination therapies, temporally sequencing of therapies, improved clinical trial designs, and real-time monitoring of patient response. A rational design of drug sequencing may secure effective treatment options at the relapsed setting. Next-generation inhibitors and bispecific antibodies have the potential to overcome resistance to the BTK inhibitor ibrutinib. Immunotherapy, including chimeric antigen receptor-modified T-cell therapy, is explored for relapsed CLL. Here, recent advances that have contributed to the understanding of resistance to targeted therapies in CLL are discussed. Strategies for managing resistance are reviewed, including translational, real-world, and clinical perspectives.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Skånland SS, Mato AR. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. Blood Adv. 2021. PMID: 33570649. doi:10.1182/bloodadvances.2020003423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。